Seeking Alpha

Allergan settles Bystolic patent dispute with Ajanta

|About: Allergan plc (AGN)|By: , SA News Editor

Allergan (AGN -0.4%) has settled patent infringement litigation with would-be generic competitor Maharashtra, India-based Ajanta Pharma Limited related to hypertension med Bystolic (nebivolol).

Ajanta will be prohibited from selling its generic version in the U.S. until the patent expires in December 2021 unless granted a non-exclusive license or the patent is invalidated.

Bystolic generated $431M in U.S. sales during the first three quarters of 2019.

Try Seeking Alpha PREMIUM for unlimited analysis on AGN